Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
(2)
HACKENSACK, NJ / ACCESSWIRE / January 19, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functionality of its SaaS program, Lumin Bioinformatics. The partnership between Champions and Code Ocean will focus on enhancements involved in data integration and sharing workflows within the Lumin platform. Users will now be equipped with a robust methodology for centralizing, storing, and organizing large amounts of their own code and data within Lumin, while leveraging single tenant hosting. Users will have the ability to upload this information directly or utilize Champions computational services to assist with integration. This new functionality establishes an entire new use case for Lumin and facilitates a customized experience for our clients. Importantly, users will now have a method f
Director of Champions Oncology, Inc. (NASDAQ:CSBR), Breitfeld Philip P., sells 31,443 shares worth $356,976
According to Champions Oncology, Inc. s most recent Statement Of Changes In Beneficial Ownership - Form 4 filing with the SEC dated Dec 17 09:29 AM, company Director, Breitfeld Philip P. disclosed selling 31,443 shares at a cost of $11.35. At the time of this transaction (Dec 16), this trade was worth $356,976 in total. As of Dec 16, Breitfeld Philip P. now owns 0 shares in total worth about $0.0.
For the last few recent trades made by Champions Oncology, Inc. (NASDAQ:CSBR) Director, Breitfeld Philip P., we have the following information: Posted by
George Daniels
Share this article
Share this article
TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company s COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with KEYTRUDA
® (pembrolizumab) and chemotherapy in patients with second-line stage IV pancreatic ductal adenocarcinoma (PDAC).
A total of 43 patients initially diagnosed with unresectable stage IV metastatic PDAC, who had progressed following first-line gemcitabine-based therapy, were enrolled in the triple combination arm. Patients received motixafortide monotherapy priming treatment for five days, followed by combination cycles of motixafortide, KEYTRUDA
Champions Oncology Reports Record Quarterly Revenue of $10 1 Million baltimorestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimorestar.com Daily Mail and Mail on Sunday newspapers.